Faruqi & Faruqi Reminds West Pharmaceuticals Investors of Pending Class Action Lawsuit - Lead Plaintiff Deadline July 7, 2025 (WST)

NEW YORK – June 20, 2025 – Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST) and is reminding investors of a critical deadline in a recently filed federal securities class action lawsuit.

Investors who purchased or acquired securities of West between February 16, 2023, and February 12, 2025, and believe they have suffered financial losses are encouraged to take note. The lawsuit alleges violations of federal securities laws, though specific details of the allegations are not fully disclosed in this announcement.

Securities Litigation Partner James (Josh) Wilson of Faruqi & Faruqi, LLP, is encouraging affected investors to contact him directly to discuss their legal rights and options. The firm emphasizes the importance for investors who experienced losses during the specified period to understand the potential implications of this class action.

Key Information for Investors:

• Affected Period: February 16, 2023, through February 12, 2025
• Lead Plaintiff Deadline: July 7, 2025
• Contact: James (Josh) Wilson, Faruqi & Faruqi, LLP
• Phone: 877-247-4292 or 212-983-9330 (Ext. 1310)
• Website: [Click here for additional information]

The role of lead plaintiff is significant in a class action lawsuit. A lead plaintiff is a representative party who acts on behalf of all members of the class. This individual or group is responsible for making important decisions regarding the litigation, including the selection of lead counsel. To be considered for the role of lead plaintiff, an investor must file a motion with the court by the stated deadline.

The deadline of July 7, 2025, is crucial for investors who wish to seek appointment as lead plaintiff. Failure to meet this deadline does not preclude an investor from participating in any potential recovery, but it does prevent them from seeking the lead plaintiff role.

Faruqi & Faruqi, LLP is known for its extensive experience in securities litigation and its commitment to protecting the rights of investors. Their investigation into West Pharmaceutical Services suggests potential issues that may have impacted the company's stock price during the class period.

Market Context and Implications:

Class action lawsuits in the securities sector can introduce uncertainty for both the company and its investors. While the filing of a lawsuit does not predetermine guilt or liability, it signals potential legal challenges that could result in financial settlements or judgments. For West Pharmaceutical Services (WST), this lawsuit adds a layer of legal risk that investors may consider when evaluating their position in the stock.

The specific allegations underlying the lawsuit will be critical in determining its potential impact. Investors should monitor further developments in the case, including the court's decision on the lead plaintiff and the progression of discovery.

Investment Insights:

For investors holding WST shares purchased during the February 16, 2023, to February 12, 2025, period, understanding the details of the lawsuit is important. Contacting a securities litigation firm like Faruqi & Faruqi can provide clarity on their rights and the potential for recovery of losses.

Even for investors who purchased shares outside of this period, awareness of the lawsuit is relevant as it could potentially affect the company's future financial performance and stock valuation depending on the outcome.

Investors should consult with their financial advisors to assess how this legal development fits into their overall investment strategy and risk tolerance. The deadline to seek lead plaintiff status is approaching, making timely action important for those interested in that role.

This announcement serves as a reminder of the ongoing legal process and the steps investors can take to stay informed and potentially participate in the class action.